3 completed, 1 recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow agenT-797: new trials by email Literature Review of agenT-797 trials Research Report on agenT-797
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-11-12 |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors agenT-797, Approved ICIs - Tumor, Solid | Phase 1 | Completed | MiNK Therapeutics | 34 | 2022-01-28 | 2024-04-24 |
| agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma agenT-797 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | MiNK Therapeutics | 13 | 2021-03-29 | 2023-06-06 |
| A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS agenT-797 - Respiratory Distress Syndrome, Adult | Phase 1 | Completed | MiNK Therapeutics | 20 | 2020-09-21 | 2025-12-30 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Respiratory Distress Syndrome (1)
MiNK Therapeutics (3) · University of Wisconsin, Madison (1)
United States (4)